DENVER, CO and NEW HAVEN, Conn., April 13, 2024 /PRNewswire/ -- Biohaven Ltd.(NYSE: BHVN) announced today that 20 abstracts, including 8 oral presentations and 12 posters, will be featured this weekend starting April 13th at the 2024 American Academy of Neurology (AAN) Annual Meeting, taking place in Denver, Colorado. The presentations highlight Biohaven's leadership in neuroscience and extensive development programs evaluating novel therapies to treat neurological diseases, with abstracts covering programs that includeKv7 ion channel modulation, molecular degraders of extracellular protein (MoDEs), TRPM3 antagonism, TYK2/JAK1 inhibition, glutamate modulation, and myostatin inhibition.
Irfan Qureshi, M.D., Chief Medical Officer of Biohaven, commented, "The research being presented at the AAN Annual Meeting emphasizes Biohaven's commitment to developing new therapeutic options across a range of neurological diseases. By targeting novel mechanisms of action, differentiated from currently available treatments and other therapies in development, and following innovative science, Biohaven continues to strive for better treatments for people living with neurological disorders. We are particularly honored that the AAN Science Committee selected our BHV-2100 (TRPM3) abstract as an AAN Abstract of Distinction, recognizing it as the top abstract in the pain category. Following the completion of Phase 1 studies in the first half of 2024, we look forward to initiating a Phase 2 study with BHV-2100 in migraine in the second half of the year and are excited by the potential for this novel nonopioid approach to treat pain."
Vlad Coric M.D., Chief Executive Officer and Chairman of Biohaven, added, "Our leadership in neuroscience research is on full display at the AAN Annual Meeting with the breadth and depth of clinical, epidemiological, and preclinical programs highlighted in our scientific presentations. Central nervous system (CNS) disorders continue to represent one of the highest unmet medical needs facing our society and we must act urgently to bring better treatments to patients and improve clinical outcomes. We believe that the next generation of therapies for CNS disorders will include MoDEs for autoimmune disorders, ion channel modulation for epilepsy, migraine and other pain disorders, immune modulation for neurodegenerative disorders including Parkinson's and Alzheimer's diseases, myostatin targeting drugs for neuromuscular disorders and glutamate modulating agents for neuropsychiatric disorders. I am so proud of the team at Biohaven who are working tirelessly to alleviate the burden of these devastating disorders."
The complete list of Biohaven's accepted abstract titles is below. Full abstracts can be viewed online at https://index.mirasmart.com/AAN2024/.
Oral Presentations:
Poster Presentations:
Posters and presentations will be available on thePosters and Presentationspage after the conference atwww.biohaven.com.
About BiohavenBiohavenis a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. The company is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms.Biohaven'sextensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA; myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates for cancer.
Forward-looking StatementsThis news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes ofBiohaven'splanned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicableU.S.regulatory requirements; the potential commercialization ofBiohaven'sproduct candidates; the potential forBiohaven'sproduct candidates to be first in class therapies; and the effectiveness and safety ofBiohaven'sproduct candidates. Additional important factors to be considered in connection with forward-looking statements are described inBiohaven'sfilings with theSecurities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, andBiohavendoes not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact:Jennifer Porcelli Vice President, Investor Relations [emailprotected] 201-248-0741
Media Contact:Mike Beyer Sam Brown Inc. [emailprotected] 312-961-2502
MoDE is a trademark of Biohaven Therapeutics Ltd.
Biohaven AAN 2024 Oral & Poster Presentations:
Functional Impairments in Patients with KCNQ2-DEE: Associations Among Key Clinical Features Sunday 4/14/24: 8:00-9:00 P1- Poster Session 1 Colorado Convention Center Exhibit Hall B-E
The Phase 3 RESILIENT Study: Taldefgrobep Alfa in Spinal Muscular Atrophy Sunday 4/14/24: 11:45 - 12:45 P2 - Poster Session 2 Colorado Convention Center - Exhibit Hall
Association of Anti-inflammatory Therapy Use with the Incidence of Parkinson's Disease: A Person-Time Analysis Among Patients with Autoimmune Diseases Sunday 4/14/24: 1:00-3:00 (1:24-1:36) S2 Movement Disorders: Epidemiology and Clinical Aspects Colorado Convention Center- Mile High 4CD
Re-weighting MDS-UPDRS Motor Items for Optimal Sensitivity to Parkinson's Disease Progression in Untreated Patients Using Parkinson's Progression Markers Initiative Data Sunday 4/14/24: 1:00-3:00 (1:36-1:48) S2 Movement Disorders: Epidemiology and Clinical Aspects Colorado Convention Center- Mile High 4CD
Population Pharmacokinetic Modeling of Riluzole After Administration of a Next Generation Prodrug Troriluzole Sunday 4/14/24: 1:00 - 3:00 (2:12-2:24) S3 - General Neurology 1 Colorado Convention Center - Four Seasons 2/3
Next Generation Prodrug Troriluzole: Increased Bioavailability of Riluzole with No Food Effect in Healthy Subjects Sunday 4/14/24: 3:30 - 5:30 (4:30-4:42) S5 - ALS and CMT: New Therapeutic Approaches Colorado Convention Center - Four Seasons 1
BHV-2100, A First-In-Class TRPM3 Antagonist for the Treatment of Pain Monday 4/15/24: 11:15-12:15 (11:27-11:39) S13 Pain Research Colorado Convention Center 605
Troriluzole Exhibits Favorable Hepatic Safety Profile Across a Diverse Range of Disorders Monday 4/15/24: 11:45 - 12:45 P4 - Poster Session 4 Colorado Convention Center - Exhibit Hall
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Doses of a Next Generation Prodrug Troriluzole in Healthy Subjects Monday 4/15/24: 11:45 - 12:45 P4 - Poster Session 4 Colorado Convention Center - Exhibit Hall
No Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of a Next Generation Prodrug Troriluzole Monday 4/15/24: 11:45 - 12:45 P4 - Poster Session Colorado Convention Center - Exhibit Hall
Automated Video-based Characterization of Movement Quality in a Phase III Clinical Trial of Troriluzole in Subjects with Spinocerebellar Ataxia Tuesday 4/16/24: 8:00-9:00 P6- Poster Session 6 Colorado Convention Center Exhibit Hall
Psychometric Validation of the Modified-functional Scale for the Assessment and Rating of Ataxias Tuesday 4/16/24: 11:45-12:45 P7 Poster Session 7 Colorado Convention Center Exhibit Hall
Development of a Novel Composite Measure (SCACOMS) to Assess Disease Progression in Spinocerebellar Ataxia Tuesday 4/16/24: 11:45-12:45 P7 - Poster Session 7 Colorado Convention Center Exhibit Hall
Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults Tuesday 4/16/24: 5:30 - 6:30 P8 - Poster Session 8 Colorado Convention Center - Exhibit Hall
Novel, Selective Kv7.2/7.3 Potassium Channel Activator, BHV-7000, Demonstrates Dose-dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults
Tuesday 4/16/24: 5:30 - 6:30 P8 - Poster Session 8 Colorado Convention Center - Exhibit Hall
Determinants of Health-related Quality of Life of Patients with Focal Epilepsy: A Systematic Literature Review Wednesday 4/17/24: 8:00-9:00 P9- Poster Session 9 Colorado Convention Center Exhibit Hall
Characterization of BHV-7000: A Novel Kv7/2/7.3 Activator for the Treatment of Seizures Wednesday 4/17/24: 1:00-3:00 (2:00-2:12) S29- Epilepsy Diagnostics and Therapeutics Colorado Convention Center 605
Matching-adjusted Indirect Comparison of Troriluzole Versus Untreated Natural History Cohort in Spinocerebellar Ataxia Wednesday 4/17/24: 3:30-5:30 (5:06-5:18) S35 Movement Disorders: Hyperkinetic Movement Disorders Colorado Convention Center Four Seasons 4
Re-weighting MDS-UPDRS Part II Items for Optimal Sensitivity to Parkinson's Disease Progression Using Parkinson's Progression Markers Initiative Natural History Data Wednesday 4/17/24: 5:30-6:30 P11 Poster Session 11 Colorado Convention Center Exhibit Hall
Novel Bispecific Degrader BHV-1300 Achieves Rapid, Robust, and Selective IgG Reduction in Preclinical Models Including Nonhuman Primates Thursday 4/18/24: 1:00 - 3:00 (1:36-1:48) S43 - General Neurology 2 Colorado Convention Center - 108/110/112
SOURCE Biohaven Ltd.
Go here to see the original:
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of ... - PR Newswire
- Unlocking Flow: The Neuroscience of Creative Bliss - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Revolutionizing Glioblastoma Treatment - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Decoding spontaneous thoughts from the brain via machine learning - EurekAlert - April 15th, 2024 [April 15th, 2024]
- Reducing Toxic AI Responses - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Advancing the neuroscience of human pregnancy - Nature.com - April 15th, 2024 [April 15th, 2024]
- Angela Bryan Awarded Hazel Barnes Prize | Psychology and Neuroscience - University of Colorado Boulder - April 15th, 2024 [April 15th, 2024]
- How Old Are You in Your Head? The Neuroscience of Subjective Age Reveals How to Stay Mentally Young - Inc. - April 15th, 2024 [April 15th, 2024]
- Those Who Use Willpower Deemed More Trustworthy - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- How Sex and Gender Shape Our Cognition - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- War's Toll on the Brain: Widespread PTSD and Anxiety Among Ukrainians - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Paints and Pesticides Linked to ALS Risk - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- AI STORIES: A New Vision for AI and Narratives - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Neuroscience Breakthrough Unveils How We Learn and Remember - SciTechDaily - April 15th, 2024 [April 15th, 2024]
- Pregnancy's Toll: Accelerated Aging in Young Mothers - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Learning and Memory Formation's Molecular Basis - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Acetaminophen in Pregnancy Not Linked to Autism, ADHD Risk - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Childhood Loneliness Linked to Later Psychosis - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Vigil Neuroscience, Inc. (NASDAQ:VIGL) Expected to Post Q1 2024 Earnings of ($0.58) Per Share - Defense World - March 29th, 2024 [March 29th, 2024]
- International Brain Research Organisation (IBRO) Diversity Grants 2024 Opportunity Desk - Opportunity Desk - March 29th, 2024 [March 29th, 2024]
- Hereditary Alzheimer's Transmitted Via Bone Marrow Transplants - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Household Chemicals Linked to Brain Health Risks - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Cheers to Longevity: Couples Who Drink Together, Live Longer - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Sleeplessness Makes You Feel Up To Ten Years Older - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Aging Brain Cells Have Prolonged Death Process - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Anxiety Drives Wishful Thinking to Risky Levels - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Prolonged Progestogen Use Linked to Brain Tumor Risk - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- The Genetic Secrets of Neuron Formation - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Yahoo Finance - March 29th, 2024 [March 29th, 2024]
- Big research, little time: Medical neuroscience student wins 3 Minute Thesis finals - Dal News - March 29th, 2024 [March 29th, 2024]
- The new NeuroAI - Nature.com - March 29th, 2024 [March 29th, 2024]
- Exploring Aphantasia: The Mind Without a Mental Picture - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Altered Brain pH Linked to Cognitive Disorders - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Emotion vs. Reason: Rethinking Decision-Making - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- DNA Damage and Inflammation Key to Memory Formation - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Embracing Neurodiversity: Beyond Stigma to Strength - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Devil in the Details: The Visual World of Prosopometamorphopsia - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Rockefeller Neuroscience Institute receives $2M grant for ultrasound drug addiction treatments - Health Imaging - March 29th, 2024 [March 29th, 2024]
- Empathy Begins in Infancy - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Mapping Brain Activity with Brain-Computer Interface Technology - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Want Better Mental Focus? Neuroscience Just Found This Simple, Joyful Activity Helps Your Brain Concentrate - Inc. - March 29th, 2024 [March 29th, 2024]
- The neuroscience of groove: Why certain rhythms make us want to dance - PsyPost - March 29th, 2024 [March 29th, 2024]
- High Rates of Suicidal Ideation in Rural Black Men - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Harmony in Chaos: How BPD Influences Music Tastes - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- WVU Rockefeller Neuroscience Institute receives $2M Grant - WDTV - March 29th, 2024 [March 29th, 2024]
- Study Links Diet, Diabetes, and Alzheimers - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Neuroscience and Society Series: Aligning Science with the Public's Values - The Hastings Center - March 29th, 2024 [March 29th, 2024]
- Hardwiring Your Brain: The Neuroscience Of Behaviour Change | TheHealthSite.com - TheHealthSite - March 29th, 2024 [March 29th, 2024]
- Refined Carb Intake's Effect on Facial Attractiveness - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Linking Childhood Adversity to Adult Mental Health - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Overnight neuronal plasticity and adaptation to emotional distress - Nature.com - March 11th, 2024 [March 11th, 2024]
- Less Obesity and Depression in NPD Individuals - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Unlocking Creative Flow: How the Brain Enters the Zone - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Self-Control, Not Impulsivity, Paves the Way to Power - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- 3D Maps Reveal Molecular Complexities of the Brain - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Loneliness Linked to Personality Disorders - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Gen Z's Climate Anxiety: A Call for Action and Hope - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Decoding Emotions: Beyond Senses in the Human Brain - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Brain Circuit Balances Speech and Breath - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Schizophrenia and Aging Share Brain Changes - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Monitoring Spinal Cord Activity During Surgery in Real-Time - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Scientists team up with jazz musicians to reveal the neuroscience of creative flow - PsyPost - March 11th, 2024 [March 11th, 2024]
- Peer Pressure Persists Through Adulthood - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Mary Bartlett Bunge, 92, Dies; Pioneer in Spinal Injury Treatment - The New York Times - March 11th, 2024 [March 11th, 2024]
- Rethinking Reminiscence: Theater's Ageism Dilemma Unveiled - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- PTSD: Virtual Reality and Magnetic Stimulation Provide Relief - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- The Partisan Morality Divide: When Politics Shapes Right and Wrong - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Biological Sciences Professor Terrence Sejnowski Wins Brain Prize - University of California San Diego - March 11th, 2024 [March 11th, 2024]
- Pioneering work in computational and theoretical neuroscience is awarded the world's largest brain research prize - afp.com - March 11th, 2024 [March 11th, 2024]
- Substance Abuse Beyond Dopamine and Impulsivity - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Pioneering work in computational and theoretical neuroscience is awarded the world's largest brain research prize - Business Wire - March 11th, 2024 [March 11th, 2024]
- Dal study of football players sheds light on how concussions affect the brain - Yahoo Canada Sports - March 11th, 2024 [March 11th, 2024]
- Hebrew University's Haim Sompolinsky awarded prestigious Brain Prize for pioneering neuroscience research - The Times of Israel - March 11th, 2024 [March 11th, 2024]
- Harvard neuroscientist Haim Sompolinsky awarded Brain Prize - EurekAlert - March 11th, 2024 [March 11th, 2024]
- Rhythm in the Brain: Music Exposure Influences Rhythmic Interpretation - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Physicist Haim Sompolinsky first Israeli to win largest brain science research prize - The Times of Israel - March 11th, 2024 [March 11th, 2024]
- Prestigious 2024 Brain Prize awarded to Hebrew University's Prof. Haim Sompolinsky by Lundbeck Foundation - EurekAlert - March 11th, 2024 [March 11th, 2024]
- Pioneering work in computational and theoretical neuroscience is awarded the world's largest brain research prize - EurekAlert - March 11th, 2024 [March 11th, 2024]
- Role of AI in Neuroscience Research and Understanding of the Human Brain - Medriva - February 13th, 2024 [February 13th, 2024]
- Healis selected to present at key biotechnology and neuroscience investor conferences in Amsterdam, New York, - EIN News - February 13th, 2024 [February 13th, 2024]
- Brain's Method for Preserving Cognition in Aging Revealed - Neuroscience News - February 13th, 2024 [February 13th, 2024]